Cypherpunk Technologies Inc.

CYPH
$0.61 (- $0.00 - 0.25%)
Last updated: 2026-06-25 16:31 UTC
CYPH Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorFinancial Services
IndustryAsset Management
ISINUS52187K2006
CUSIP52187K200
Market Price0.61
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-1.22
Market Cap$68.0M
Book Value0.07
Price to Book18.462
Beta-0.14
52w High3.7
52w Low0.22
Next Earnings DateN/A

Cypherpunk Technologies Inc. trades under ticker CYPH on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Financial Services exposure. Identifiers: ISIN US52187K2006, CUSIP 52187K200.

About the Company
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.
Price History